15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $606M | -$1.3B | 79.7% | -205.6% | -172.8% | -56.4% | -$968M | $547M | $510M |
| 2024 | $364M | -$914M | 76.4% | -241.5% | -320.2% | -45.1% | -$706M | $1.1B | $555M |
| 2023 | $305M | -$750M | 78.5% | -232.5% | 225.8% | -56.4% | -$550M | $1.2B | $482M |
| 2022 | $245M | -$482M | 77.5% | -186.4% | -547.5% | -29.1% | -$410M | $1.2B | $1.1B |
| 2021 | $188M | -$435M | 76.6% | -199.0% | -105.9% | -35.0% | -$371M | $800M | $717M |
| 2020 | $164M | -$294M | 75.7% | -161.3% | -106.6% | -36.9% | -$226M | $450M | $533M |
| 2019 | $136M | -$254M | 82.3% | -172.4% | -97.2% | -34.3% | -$293M | $450M | $487M |
| 2018 | $10M | -$324M | 75.4% | -3124.9% | -155.7% | -53.6% | -$271M | $450M | $495M |
| 2017 | $0 | -$193M | — | — | -53.4% | -41.7% | -$163M | $55M | $381M |
| 2016 | $0 | -$176M | — | — | -114.1% | -74.1% | -$151M | $55M | $163M |
| 2015 | — | -$118M | — | — | -37.9% | -33.1% | -$104M | $25M | $283M |
| 2014 | — | -$79M | — | — | -42.5% | -34.3% | — | $25M | $159M |
| 2013 | — | -$56M | — | — | -39.1% | -31.8% | — | $20M | $114M |
| 2012 | — | -$41M | — | — | -34.2% | -26.9% | -$31M | $20M | $91M |
| 2011 | — | -$60M | — | — | -44.4% | -42.7% | -$31M | $0 | $15M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $425M | -$13M | 84.2% | -0.4% | -1.7% | -0.6% | -$95M | $547M | $545M |
| Mar '26 | $306M | -$164M | 84.5% | -50.1% | -23.2% | -7.9% | -$226M | $547M | $582M |
| Dec '25 | $264M | -$328M | 83.2% | -121.2% | -44.5% | -14.5% | -$264M | $547M | $510M |
| Sep '25 | $142M | -$370M | 79.4% | -257.1% | -39.1% | -15.7% | -$222M | $547M | $335M |
| Jun '25 | $107M | -$322M | 73.9% | -291.3% | -25.7% | -13.0% | -$209M | $547M | $1.3B |
| Mar '25 | $93M | -$257M | 77.1% | -267.3% | -258.8% | -14.2% | -$272M | $1.1B | $403M |
| Dec '24 | $104M | -$236M | 75.0% | -220.6% | -82.5% | -11.6% | -$203M | $1.1B | $555M |
| Sep '24 | $93M | -$221M | 77.3% | -228.4% | -45.6% | -10.7% | -$185M | $972M | $461M |
| Jun '24 | $90M | -$301M | 76.8% | -319.8% | -774.4% | -16.6% | -$130M | $1.2B | $1.2B |
| Mar '24 | $76M | -$157M | 76.9% | -192.7% | 33.8% | -13.6% | -$189M | $1.2B | $596M |
| Dec '23 | $84M | -$186M | 78.0% | -213.0% | 56.1% | -14.0% | -$133M | $1.2B | $482M |
| Sep '23 | $79M | -$159M | 78.9% | -186.8% | 54.9% | -12.0% | -$139M | $1.2B | $487M |
| Jun '23 | $77M | -$245M | 78.5% | -305.0% | 157.2% | -17.0% | -$128M | $1.2B | $613M |
| Mar '23 | $65M | -$160M | 78.8% | -227.2% | 357.8% | -10.5% | -$150M | $1.2B | $969M |
| Dec '22 | $59M | -$160M | 78.0% | -255.4% | -182.1% | -9.7% | -$108M | $1.2B | $1.1B |
| Sep '22 | $68M | -$131M | 80.1% | -188.5% | 437.7% | -13.2% | -$90M | $800M | $415M |
| Jun '22 | $65M | -$96M | 74.9% | -135.4% | -216.2% | -9.1% | -$105M | $800M | $416M |
| Mar '22 | $53M | -$95M | 77.0% | -169.2% | -78.9% | -8.2% | -$107M | $800M | $516M |
| Dec '21 | $56M | -$113M | 76.3% | -176.5% | -27.5% | -9.1% | -$85M | $800M | $717M |
| Sep '21 | $47M | -$113M | 78.2% | -221.6% | -22.3% | -8.6% | -$77M | $800M | $847M |
How the market has priced INSM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Insmed Incorporated's revenue has grown 29.8% per year. These are computed facts, not advice.
As of FY2025, Insmed Incorporated reported $547M of total debt against $510M of cash; operating income covered interest expense -14.9×.
In FY2025, gross margin was 79.7%, operating margin -205.6%, and net margin -210.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.